Purpose: We performed a prospective noncomparative study to report the results of reduced fluence photodynamic therapy (PDT) combined with intravitreal ranibizumab in patients with polypoidal choroidal vasculopathy with active exudation and hemorrhage. Methods: Seventeen polypoidal choroidal vasculopathy eyes were treated, and followup for all patients was 12 months. Photodynamic therapy was administered with reduced fluence (exposure time of 70’’) and followed (48 hours later) by intravitreal ranibizumab (0.5 mg in 50 mL). Intravitreal ranibizumab, with or without reduced fluence PDT, was repeated as indicated by clinical and angiographic findings. Results: During the follow-up, the mean best-corrected visual acuity significantly improved from 0.45 ± 0.29 logarithm of the minimum angle of resolution at baseline to 0.29 ± 0.28 logarithm of the minimum angle of resolution at 12 months. The mean total macular volume (documented by optical coherence tomography retinal map examination) decreased from 7.5 ± 1.18 mm3 to 6.7 ± 0.8 mm3. In 95% of the cases, best-corrected visual acuity remained stable or improved. Conclusion: Reduced fluence PDT limits laser exposure, minimizing the risks of PDTinduced adverse effects. Intravitreal injections of ranibizumab 0.5 mg reduced bleeding and leakage in polypoidal choroidal vasculopathy eyes and interfere with rebound upregulation of vascular endothelial growth factor because of PDT-induced choroidal hypoperfusion. Combined treatment may improve treatment outcomes in polypoidal choroidal vasculopathy while minimizing ocular and systemic complications of treatment.

Ricci, F., Calabrese, A., Regine, F., Missiroli, F., & Ciardella, A. (2012). Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy. RETINA, 32(7), 1280-1288 [10.1097/IAE.0b013e318236e835].

Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy

RICCI, FEDERICO;MISSIROLI, FILIPPO;
2012

Abstract

Purpose: We performed a prospective noncomparative study to report the results of reduced fluence photodynamic therapy (PDT) combined with intravitreal ranibizumab in patients with polypoidal choroidal vasculopathy with active exudation and hemorrhage. Methods: Seventeen polypoidal choroidal vasculopathy eyes were treated, and followup for all patients was 12 months. Photodynamic therapy was administered with reduced fluence (exposure time of 70’’) and followed (48 hours later) by intravitreal ranibizumab (0.5 mg in 50 mL). Intravitreal ranibizumab, with or without reduced fluence PDT, was repeated as indicated by clinical and angiographic findings. Results: During the follow-up, the mean best-corrected visual acuity significantly improved from 0.45 ± 0.29 logarithm of the minimum angle of resolution at baseline to 0.29 ± 0.28 logarithm of the minimum angle of resolution at 12 months. The mean total macular volume (documented by optical coherence tomography retinal map examination) decreased from 7.5 ± 1.18 mm3 to 6.7 ± 0.8 mm3. In 95% of the cases, best-corrected visual acuity remained stable or improved. Conclusion: Reduced fluence PDT limits laser exposure, minimizing the risks of PDTinduced adverse effects. Intravitreal injections of ranibizumab 0.5 mg reduced bleeding and leakage in polypoidal choroidal vasculopathy eyes and interfere with rebound upregulation of vascular endothelial growth factor because of PDT-induced choroidal hypoperfusion. Combined treatment may improve treatment outcomes in polypoidal choroidal vasculopathy while minimizing ocular and systemic complications of treatment.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/30 - Malattie Apparato Visivo
eng
Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Choroid; Choroid Diseases; Coloring Agents; Combined Modality Therapy; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Indocyanine Green; Intravitreal Injections; Male; Middle Aged; Photochemotherapy; Polyps; Prospective Studies; Ranibizumab; Retreatment; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity
Ricci, F., Calabrese, A., Regine, F., Missiroli, F., & Ciardella, A. (2012). Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy. RETINA, 32(7), 1280-1288 [10.1097/IAE.0b013e318236e835].
Ricci, F; Calabrese, A; Regine, F; Missiroli, F; Ciardella, A
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
combined.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 458.76 kB
Formato Adobe PDF
458.76 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/137047
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 27
social impact